Elucidating the specific pharmacological mechanism of motion (MOA) of naturally occurring compounds is usually challenging. Even though Tarselli et al. (sixty) designed the main de novo synthetic pathway to conolidine and showcased that this naturally developing compound properly suppresses responses to both of those chemically induced and inflamma